相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Technical and Biological Issues Relevant to Cell Typing with Aptamers
Na Li et al.
JOURNAL OF PROTEOME RESEARCH (2009)
Recognition of biomarkers and cell-specific molecular signatures: Aptamers as capture agents
Arthur A. Neryl et al.
JOURNAL OF SEPARATION SCIENCE (2009)
Rabbit antibody detection with RNA aptamers
Yoshihito Yoshida et al.
ANALYTICAL BIOCHEMISTRY (2008)
New strategies for in vivo tissue engineering by mimicry of homing factors for self-endothelialisation of blood contacting materials
Meltem Avci-Adali et al.
BIOMATERIALS (2008)
Bevacizumab and irinotecan in the treatment of recurrent malignant gliomas
John F. de Groot et al.
CANCER JOURNAL (2008)
Anticoagulation in patients with acute ischemic stroke and atrial fibrillation-a balance of risks and benefits
Abhimanyu Beri et al.
CARDIOVASCULAR DRUGS AND THERAPY (2008)
Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease
Mark Y. Chan et al.
CIRCULATION (2008)
Aptamers as candidate therapeutics for cardiovascular indications
Anthony D. Keefe et al.
CURRENT OPINION IN PHARMACOLOGY (2008)
A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor
M. Y. Chan et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2008)
First-in-human evaluation of anti-von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers
James C. Gilbert et al.
CIRCULATION (2007)
AS1411 alters the localization of a complex containing protein arginine methyltransferase 5 and nucleolin
Yun Teng et al.
CANCER RESEARCH (2007)
Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102
Barbara Sennino et al.
CANCER RESEARCH (2007)
Monoclonal antibody mechanisms of action in cancer
George J. Weiner
IMMUNOLOGIC RESEARCH (2007)
First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology - A phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity
Christopher K. Dyke et al.
CIRCULATION (2006)
Discovery and development of anticancer aptamers
Christopher R. Ireson et al.
MOLECULAR CANCER THERAPEUTICS (2006)
A new technique for the isolation and surface immobilization of mesenchymal stem cells from whole bone marrow using high-specific DNA aptamers
Ke-Tai Guo et al.
STEM CELLS (2006)
A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery
Shahid M. Nimjee et al.
MOLECULAR THERAPY (2006)
Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras
James O. McNamara et al.
NATURE BIOTECHNOLOGY (2006)
AGRO100 inhibits activation of nuclear factor-κB (NF-κB) by forming a complex with NF-κB essential modulator (NEMO) and nucleolin
Allicia C. Girvan et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Aptamer:toxin conjugates that specifically target prostate tumor cells
Ted C. Chu et al.
CANCER RESEARCH (2006)
Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular enclothelial growth factor therapy in multiple models of ocular neovascularization
Nobuo Jo et al.
AMERICAN JOURNAL OF PATHOLOGY (2006)
Intraocular injection of an aptamer that binds PDGF-B: A potential treatment for proliferative retinopathies
H Akiyama et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2006)
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo
OC Farokhzad et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease
EWM Ng et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Aptamer mediated siRNA delivery
Ted C. Chu et al.
NUCLEIC ACIDS RESEARCH (2006)
DNA and RNA aptamers: From tools for basic research towards therapeutic applications
Henning Ulrich et al.
COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING (2006)
PDGFRβ+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival
S Song et al.
NATURE CELL BIOLOGY (2005)
Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration
EWM Ng et al.
CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE (2005)
In vitro selection of high-affinity DNA ligands for human IgE using capillary electrophoresis
SD Mendonsa et al.
ANALYTICAL CHEMISTRY (2004)
Pegaptanib for neovascular age-related macular degeneration
ES Gragoudas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Vascular endothelial growth factor: Basic science and clinical progress
N Ferrara
ENDOCRINE REVIEWS (2004)
Pharmacokinetics and biodistribution of novel aptamer compositions
JM Healy et al.
PHARMACEUTICAL RESEARCH (2004)
RNA and DNA aptamers in cytomics analysis
H Ulrich et al.
CYTOMETRY PART A (2004)
Aptamer database
JF Lee et al.
NUCLEIC ACIDS RESEARCH (2004)
Nanopartide-aptamer bioconjugates: A new approach for targeting prostate cancer cells
OC Farokhzad et al.
CANCER RESEARCH (2004)
Recruitment of marrow-derived endothelial cells to experimental choroidal neovascularization by local expression of vascular endothelial growth factor
KG Csaky et al.
EXPERIMENTAL EYE RESEARCH (2004)
Spiegelmers: Biostable aptamers
D Eulberg et al.
CHEMBIOCHEM (2003)
Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors
G Bergers et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
VEGF164 is proinflammatory in the diabetic retina
S Ishida et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2003)
RNA aptamers as reversible antagonists of coagulation factor IXa
CP Rusconi et al.
NATURE (2002)
In vitro selection of RNA aptamers that bind to cell adhesion receptors of Trypanosoma cruzi and inhibit cell invasion
H Ulrich et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Systematic evolution of a DNA aptamer binding to rat brain tumor microvessels - Selective targeting of endothelial regulatory protein pigpen
M Blank et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1)
K Miyamoto et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
分享论文
